DEBIOPHARM APPLIES FOR FIRST EUROPEAN MARKETING AUTHORISATION FOR SANVAR IN FRANCE

The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions filed a French marketing authorisation application (MAA) for Sanvar in the treatment of patients with esophageal variceal bleeding (EVB). Debiopharm intends to apply for wider European approval through the Mutual Recognition Procedure (MRP), in which France will serve as Reference Member State. Debiopharm is seeking partners for the European commercialisation of Sanvar.

Drug Newswire (http://www.drugnewswire.com/3772/)